Cyproterone Acetate (Androcur®)

Common name: Cyproterone Acetate
Brand name: Androcur®
 

What is Cyproterone Acetate?

Cyproterone Acetate is an anti-androgen therapy used to treat advanced prostate cancer. It works by slowing or stopping the production of testosterone in the body to slow the growth of prostate cancer cells.
 

How is Cyproterone Acetate administered?

Cyproterone Acetate is administered either orally as a tablet or as an intramuscular injection.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received cyproterone acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Hair loss
  • Impotence
  • Increased bowel movements
  • Increased hair growth
  • Loss of energy
  • Reduced sexual interest
  • Weight gain
 

Is Cyproterone Acetate covered in my province or territory?

Cyproterone acetate is covered by all provincial/territorial drug programs.
 
Last Reviewed: July 2017



Plaid for Dad


Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Honouring dad this Father’s Day the Canadian way: In plaid

TORONTO, ON – (May 8, 2018) – Plaid replaces business-casual on Friday, June 15 as hundreds of thousands of Canadians don the iconic Canadian attire all to honour dad and end prostate cancer.
More

The Finger – A tried and true method to save lives

TORONTO, CANADA (May 8, 2018) – Every day, more and more methods to detect prostate cancer are being explored, but the tried and true methods of a digital rectal examination (DRE) – where a healthcare professional inserts a gloved finger into the rectum to check for abnormalities, paired with a blood test known as the prostate-specific antigen (PSA) test – which you can get through your family doctor, are still the long-standing proven ways to save a life.
More

Landmark study links tumour evolution to prostate cancer severity

Toronto (April 19, 2018) – Findings from Canadian Prostate Cancer Genome Network (CPC-GENE) researchers and their collaborators, published today in Cell, show that the aggressiveness of an individual prostate cancer can be accurately assessed by looking at how that tumour has evolved.
More


Click here for news archive